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The product encoded by the X-linked inhibitor of apoptosis (XIAP) gene is a 
multi-functional protein which not only controls caspase-dependent cell 
death, but also participates in inflammatory signalling, copper homeostasis, 
response to hypoxia and control of cell migration.  Deregulation of XIAP, 
either by elevated expression or inherited genetic deletion, is associated 
with several human disease states.  Reconciling XIAP-dependent signalling 
pathways with its role in disease progression is essential to understand how 
XIAP promotes the progression of human pathologies.  In this study we have 
created a panel of genetically modified XIAP-null cell lines using TALENs 
and CRISPR/Cas9 to investigate the functional outcome of XIAP deletion.  
Surprisingly, in our genetically modified cells XIAP deletion had no effect on 
programmed cell death, but instead the primary phenotype we observed was 
a profound increase in cell migration rates.  Furthermore, we found that 
XIAP-dependent suppression of cell migration was dependent on XIAP-
dependent control of C-RAF levels, a protein kinase which controls cell 
signalling pathways that regulate the cytoskeleton.   These results suggest 
that XIAP is not necessary for control of the apoptotic signalling cascade, 
however it does have a critical role in controlling cell migration and motility 




The Inhibitors of apoptosis (IAP) proteins are a family of functionally and 
structurally related proteins predominantly known for the regulation of caspases 
and immune signalling 1. In mammalian cells there are eight IAP family members 
all characterised by the presence of at least one baculovirus repeat (BIR), the 
domain utilized by viral IAP proteins to compromise host cell death machinery 2.  
Of the 8 mammalian IAP family members the X-linked IAP (XIAP) is perhaps the 
best-characterized, with the most direct links to human disease 3,4 .  XIAP contains 
3 BIR domains located on the amino terminus of the protein that allow XIAP to 
inhibit apoptotic cell death. In fact XIAP is the only mammalian IAP protein that has 
the capacity to directly bind to and functionally inhibit caspases; specifically 
caspase-3, caspase-7 and caspase-9, to suppress apoptosis 5–7.  In addition to the 
BIR domains XIAP contains a carboxy-terminal RING domain that provides it with 
E3 ubiquitin ligase activity, as well as a ubiquitin associated domain (UBA) that 
can interact with ubiquitin chains (Figure 1A)  8,9,10,11.  This enables XIAP to 
participate in multiple ubiquitin-dependent signal transduction cascades enabling 
it to act as a key intermediate in a variety of cellular pathways including, but not 
limited to: NF-κB signalling 3,12,13, MAPK/JNK signalling 14, maintenance of 
intracellular copper levels 15–17, hypoxia-induced gene expression 18, Wnt/ b-
catenin signalling 19, regulation of autophagy 20–22  and control of  cell motility and 
migration 23, 24–27, 28.  Due to its key role in signal transduction pathways, 
deregulation of XIAP has been implicated in the pathogenesis of human cancers 
and inflammatory diseases 3.  XIAP is highly overexpressed in many forms of 
cancer, including breast 29, renal 30,31, bladder 32 and certain haematological 
malignancies 33.  Indeed, a systematic review correlates high XIAP expression and 
poor patient outcomes in a variety of solid tumours 34. Conversely, inactivating 
genetic mutations in the XIAP gene can result in an extremely rare primary 
immunodeficiency in humans, Type 2 X-linked lymphoproliferative disease (XLP2), 
characterised by a defective immune system that is powerfully responsive to 
infection with the Epstein-Barr virus (EBV) 4,35,36.  It is therefore important to 
reconcile the molecular properties of XIAP with its role in the progression of human 
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disease states to understand the critical roles of XIAP, so as to facilitate the 
development of novel therapeutics.   
To study the cellular function of XIAP we created XIAP-null human cell lines 
using site directed nucleases and compared their properties with isogenic wildtype 
controls.  Surprisingly, we find no obvious defects in the induction of caspase-
dependent apoptosis in XIAP-deficient cell lines.  Instead, the primary XIAP-
dependent defect we observe is an increase in cell migration in XIAP-null cells.  
We find that levels of C-RAF protein kinase are elevated in XIAP-null cells, 
consistent with increased cell migration rates.  Re-expression of XIAP was 
sufficient to reduce C-RAF levels and suppress the motility of XIAP-null cells.  
However, introduction of an XIAP mutant that does not have E3 ligase activity did 
not reverse the invasive phenotype, indicating that control of cell migration by XIAP 
relies on its ability to ubiquitinate substrates.  Together our results suggest that 
XIAP is critical for modulating cell motility in a manner dependent on its ability to 
conjugate ubiquitin to target substrates.     
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Materials and Methods 
 
Cells 
U2OS and HeLa cells were sourced from the ATCC and grown in DMEM 
supplemented with 10% FBS, 1% L-gluatamine, and 1% penicillin streptomycin at 
37 °C and 5% CO2. Cells were routinely tested for contamination.   
 
Plasmids  
pEBB-HA, pEBB-HA-XIAP, pEBB-HA-XIAP-D148A/W310, pEBB-HA-XIAP-F495A 
were kind gifts from Colin Duckett (Duke University).  CRISPR/ Cas9 and TALEN 
constructs are described in the relevant sections.   
 
CRISPR/Cas9 Genome Editing 
CRISPR/Cas9 gRNAs were designed using using zifit.partners.org.  The oligos 5’ 
ACACCGCATCAACACTGGCACGAGCG 3’ and 5’ 
AAAACGCTCGTGCCAGTGTTGATGCG 3’  were annealed and cloned into the 
vector MLM3636 (Addgene #43860) cut with BsmBI. The CRISPR gRNA plasmid 
was transfected with the JDS246 (Addgene plasmid #43861) a  mammalian codon 
optimized Cas9 nuclease with C-term 3X FLAG, using Genejuice transfection 
reagent (Merck) according to the manufacturer’s instructions.  Clonal cell lines 
were isolated by limiting dilution.  Genomic DNA was isolated using DirectPCR 
lysis buffer (Viagen).  Gene disruption was analysed by PCR using primers 
spanning the CRISPR gRNA binding region Sense 5’- aaagtctgttgcttgtgtttca – 3’ 
and Antisense 5’ taccagaatttgtagactgcgt- 3’ and a PCR control region downstream 
of the CRISPR gRNA binding site to check quality of the genomic DNA 
preparations.  Sequencing reactions were performed using the custom primer 5’ 
tgacaactaaagcaccgcac 3’. 
 
TALEN Genome Editing 
TALENS pairs were designed using the algorithm on zifit.partners.org.  TALE 
repeats were created by nested PCR and cloned into the FokI containing plasmids 
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JDS71 (Addgene #32285) for the Left TALEN (binding to the DNA sequence 
TCCTGTTTCAGCATCAAC) and JDS70 (Addgene #32285) for the Right TALEN 
(binding to the DNA sequence TTCACCAGTATAAAGAAA).  The TALEN pair is 
predicted to create a DNA double strand after the base pair 145 within exon 1 of 
the XIAP gene, corresponding to amino acid Arginine 48.  TALEN transfections 
were performed using the Amaxa nucleofector, using the nucleofector kit V using 
the X-001 program.  Clonal cell lines were isolated by limiting dilution and 
characterized using the same primer pairs used for the CRISPR/ Cas9 lines. 
 
Wound healing assay 
Cells were seeded onto 6 well plates at a density of 25000 cells/well and incubated 
at 37ºC for 72 hours. A scratch was made across the well using a sterile pipette tip 
and cultured in fresh media. A line was drawn perpendicular to the scratch and an 
image was taken of the scratch underneath the line using an EVOS XL Core 
microscope. Plates were marked perpendicular to the scratch to ensure the same 
area was imaged at each time point.  The wounds were imaged at 0, 6, 24 and 28 
hours after the scratch was made. The area of the wound was measured at each 
time point using ImageJ software and normalised to 100% at time 0.  The data 
were plotted using GraphPad PRISM and the area underneath the curve was 
quantified.  Each data point represents the area calculated from the closure of a 
single scratch.  Statistical analysis was performed by Student’s T-test or  one-way 
ANOVA with Dunnett’s multiple comparisons test. Where specified, the area under 
the curve was calculated and analysed using this method. A value of p<0.05 was 
considered to be statistically significant. 
 
Cell viability studies: 
Cells were seeded into 96 well plates at a density of 5000 cells/well and incubated 
at 37ºC overnight. Etoposide (Sigma) or doxorubicin (Sigma) was diluted in 
supplemented DMEM to achieve a gradient of drug concentrations as specified in 
the figure legend. This was incubated at 37ºC for 48 hours, after which the media 
was removed and 100μl of 5% PrestoBlue® (Invitrogen) diluted in supplemented 
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DMEM was pipetted into each well. After 2 hours’ incubation at 37ºC, 90μl from 
each well was pipetted into a new 96 well plate and the fluorescence intensity was 
recorded at 570 nm using POLAR star Omega plate reader.  The cell viability was 
expressed as a percentage relative to untreated controls. 
 
Immunoblotting and antibodies 
Immunoblot analysis was performed as described in 37. Briefly, cell lysates were 
prepared with modified RIPA lysis buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% 
NP40, 0.5% C24H39NaO4, 0.1% SDS) supplemented with protease inhibitors and 
incubated on ice for 15 min. Lysates were then sonicated in a Biodisrupter Ultra-
Sonic Waterbath (Diagenode) (2 × 30 s cycles on high) to shear the genomic DNA 
and clarified by centrifugation at 13 000 rpm at 4°C for 10 min.  Protein 
concentration was determined by BCA assay and 20 μg of protein was loaded per 
well. Immunoblotting was performed using the following antibodies: β-actin (AC-
74, Sigma), XIAP (610762, BD Transduction Laboratories), XIAP (ab28151, 
Abcam), cIAP1 (1E1-1-10, Enzo Life Sciences), C-RAF (A301-519A, Bethyl 
Laboratories) Rac1/Cdc42 (#4651, Cell Signalling Technologies) and Actin (Ac-
74, Sigma). 
 
Caspase activity assay 
Cells were seeded into 96-well plates at a density of 5000 cells/well. The following 
day cells were treated as indicated and the caspase activity was determined using 
Caspase-Glo assay (Promega) according to the manufacturer's protocol.  Raw 
RLU values are presented and statistical analysis performed using a one-way 
ANOVA with Dunnett’s multiple comparisons test.  A value of p<0.05 was 
considered to be statistically significant. 
 
Proliferation experiment 
Clonal cell lines were seeded into 96 well plates at a density of 2500 cells/well. 
The plates were incubated at 37ºC and measured using 5% PrestoBlue® (as 
described above) after either 24, 48, 72 or 96 hours incubation. The gain was 
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determined after 24 hours and was subsequently used to measure all plates to 
allow for comparison between time points.  Raw values were plotted to indicate 




siRNA duplex oligonucleotides were synthesised by MWG and transfected using 
Interferin (Polyplus) according to the manufacturer's instructions. siRNA 
sequences: control—CAG UCG CGU UUG CGA CUG G; XIAP —GUG GUA GUC 
CUG UUU CAG C. 
 
Statistical analysis 
Statistical analysis was performed by a one-way ANOVA with Dunnett’s multiple 
comparisons test or unpaired Student’s t-test where appropriate. Where specified, 
the area under the curve was calculated and analysed using these methods.  If a 
p-value is less than 0.05, it is flagged with one star (*). If a p-value is less than 
0.01, it is flagged with two stars (**). If a p-value is less than 0.001, it is flagged 




Creation of XIAP-null cell lines 
To disrupt the coding region of the XIAP gene a CRISPR guide RNA (gRNA) was 
designed to bind within the first exon of the XIAP gene (Figure 1A).  Plasmids 
encoding the CRISPR gRNA and the Cas9 nuclease were transfected into U2OS 
cells to induce DNA double strand breaks (DSBs) and disrupt the XIAP coding 
region (Figure 1A).  DBSs were induced 150bp downstream from the start site of 
translation, corresponding to glycine 50, within the first BIR of the XIAP protein 
(Figure 1A).  PCR analysis was performed on genomic DNA isolated from clonal 
cell lines using specific primers flanking the site of DSBs to assess targeted gene 
disruption (Figure 1A and 1B).  Only clones with a single PCR product, indicating 
homozygosity, were taken forward for further analysis.  Three disrupted clones 
were identified; two with PCR products smaller than the wildtype (small deletion of 
the XIAP gene) (KO 1 and KO 2) and one where the PCR product was absent 
(large deletion of the XIAP gene) (KO 3) (Figure 1B).  The absence of PCR product 
from KO 3 was not due to lack of genomic DNA in the reaction, as control PCR 
primers amplifying an unrelated region of the XIAP coding sequence was efficiently 
amplified (Figure 1B).  Rather it was predicted that a primer binding site was 
deleted from exon 1.  DNA sequencing analysis revealed a 14 bp deletion in clone 
KO 1 and a 50bp deletion in clone KO 2, which both result in frameshift mutations 
within the first exon of the XIAP gene (Figure 1C).  Immunoblot analysis, using 2 
different anti XIAP monoclonal antibodies, confirmed XIAP deletion in clones KO 
1 and KO 2 and revealed that the large deletion of the XIAP gene in clone KO 3 
also resulted in the creation of a XIAP-null cell line (Figure 1D and 1E).  Together 
these results confirm 3 distinct genetic disruptions of the XIAP gene, allowing us 
to assess the effects of XIAP deletion in cells. 
  
XIAP null cells do not have increased sensitivity to cell death 
 As XIAP is best described as a suppressor of caspase-dependent cell death 
we initially examined if XIAP-null U2OS cells are more sensitive to genotoxic stress 
induced by DNA damaging agents.  Two wildtype and three independent isogenic 
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XIAP-null cell lines were treated with increasing doses of the DNA topoisomerase 
II inhibitor, etoposide, or the DNA intercalating agent, doxorubicin, both potent 
inducers of apoptotic cell death.  Depletion of XIAP levels by RNAi has previously 
been reported to increase caspase-dependent apoptotic cell death in response to 
these DNA damage inducing agents in cancer cell lines 38.  Both etoposide and 
doxorubicin both efficiently induced cell death in U2OS cells (Figure 2A and 2B, 
Supplemental Figure 1).  Surprisingly, no differences in sensitivity were observed 
that correlated with XIAP status of the cell lines (Figure 2A and 2B, Supplementary 
Figure 1).  Indeed, the IC50 values calculated for both etoposide and doxorubicin 
showed no significant differences between any of the XIAP-wildtype or XIAP-null 
cell lines tested (Figure 2C and 2D). 
  Our results indicate no differences in cell viability associated with XIAP 
status.  However, cell viability assays do not specifically measure caspase activity 
associated with apoptotic cell death, but can in fact be influenced by the cumulative 
effects of alternative cell death pathways, cell growth rates and cell metabolic 
activity.  As XIAP’s role in cell death control is through its ability to bind to, and 
inhibit, the activity of cell death effector caspases we directly measured the 
activities of caspases -3 and -7 in XIAP-null cell lines in response to etoposide.  
XIAP wildtype and XIAP-null U2OS cells were treated with etoposide and apoptotic 
cell death was determined using a luminescent assay directly measuring caspase-
3 and caspase-7 activity (Figure 2E).  Consistent with cell viability results, no 
significant differences in caspase activity in response to etoposide were observed 
between XIAP wildtype and null U2OS cell lines, indicating that loss of XIAP is not 
sufficient to alter either cell death or caspase activity in U2OS cells (Figure 2E).  
Together our data suggests that loss of XIAP has no effect on apoptotic cell death 
in response to DNA damaging agents in our genetically modified cell lines. 
 
XIAP-null cells have increased migratory capacity 
XIAP has the ability to act as an E3 ubiquitin ligase and as such is an 
important regulator of several cell signaling pathways 10,28,39.  Several studies have 
identified IAP proteins, including XIAP, as regulators of the cytoskeleton 28.  
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However, there have been conflicting reports on the specific role of XIAP in 
regulating cell motility.  There is data suggesting that elevated XIAP promotes cell 
motility 23,26 and other reports suggesting that high XIAP suppresses migration 
rates in cultured cell lines 24, 25.  We therefore decided to use XIAP-null cells to 
investigate if genetic deletion of the XIAP gene alters migration rates in U2OS 
cells.   
XIAP wildtype and null U2OS cell lines were seeded and allowed to grow to 
confluency before a scratch was created using a sterile pipette tip.  Multiple images 
of the scratch were taken over the course of the assay and area was mapped and 
measured using ImageJ software.  The data indicate that genetic deletion of XIAP 
increased the migration rates, as indicated by the enhanced closure rates of the 
wounds in XIAP-null cells (Figure 3A and Supplementary Figure 2A).  To quantify 
the migratory capacity of each clonal cell line area under the curve was calculated 
to map wound closure rates and XIAP deletion resulted in a significantly increased 
cell migration rate in each of the cell lines tested (Figure 3B and C).  To ensure 
that the increased closure of the wound healing assays in XIAP-null cells was 
indeed due to increased cell motility, and not increased cell growth/ doubling time, 
cell proliferation rates were compared between wild type and XIAP-null cells 
(Figure 3D).  No differences were seen in growth rates between wildtype and XIAP-
null cells indicating that differences in wound closure were indeed due to 
differences in cell motility rather than an increase in cell number (Figure 3D).  
Indeed, quantitative and qualitative analysis showed increased morphological 
changes and motility, in XIAP-null cells by measuring the dynamic nature of the 
migration front (Supplementary Figure 2B and 2C). 
Like all genome editing technologies CRISPR/Cas9 can induce double 
strand breaks at off-target sites within the genomes of targeted cells 40.  To ensure 
the XIAP-dependent migration phenotype was in fact due to the targeted disruption 
of the XIAP gene, rather than an off-target effect of the CRISPR gRNA, we tested 
an independent XIAP-null cell line created using transcription activator-like effector 
nucleases (TALENs), an alternative genome editing tool.  Plasmids encoding a 
TALEN pair were designed to induce a double strand break within the first exon of 
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XIAP, 145 bp downstream of the start site of translation corresponding to arginine 
48 of the XIAP protein (Supplementary Figure 3A).  Clonal cell lines were isolated 
by limiting dilutions and analysed by PCR (Supp. Figure 3B).  A clone homozygous 
for a deletion in the XIAP coding sequence was identified (Supplementary Figure 
3B).  Sequencing analysis confirmed a 10bp deletion of the XIAP coding sequence, 
predicted to result in a frame shift and premature stop codon (Supplementary 
Figure 3C).  XIAP deletion was confirmed by immunoblot analysis (Supp. Figure 
3D).  Cell motility was measured using the TALEN-XIAP null cell line and 
compared to a matched wildtype control (Supplementary Figure 3E).  TALEN-
mediated XIAP deletion resulted in extended morphology and increased cell 
motility, consistent with the results observed in the CRISPR/ Cas9 XIAP-null cell 
lines (Supplementary Figure 3D and 3E).  To investigate if our results were cell 
line specific we next tested the migratory capacity of HeLa cells in which XIAP is 
depleted by RNAi-mediated knockdown to investigate if our effects were observed 
across cell lines (Supplementary Figure 4A).  Consistent with results from 
genetically engineered cells XIAP depletion resulted in increased migratory 
capacity as measured by wound healing assay (Supplementary Figure 4B and 4C).     
Together our results indicate that XIAP deletion increases the migratory capacity 
of culture cells independently of the method used to create them. 
 
cIAP depletion does not significantly alter cell migration rates in U2OS cells 
The related cellular IAP (cIAP) proteins, cIAP1 and cIAP2, have also been 
implicated in altering cell migration rates in cultured cell lines 23,26.  As deletion of 
IAP genes can influence the protein levels of other family members through 
feedback mechanisms we analysed cIAP levels in XIAP-null cell lines 41.  A 
modest, but insignificant, increase in cIAP1 is observed in XIAP null cells 
consistent with the feedback loop observed in other cellular systems  (Figure 4A, 
Supplementary Figure 5A).  To examine the potential roles of cIAP proteins in cell 
migration, independently from XIAP, U2OS wildtype cells were treated with the 
SMAC mimetic compound, LCL 161 42.  SMAC mimetics, such as LCL 161,  
although designed to bind to XIAP have been shown to target both cIAP1 and 
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cIAP2 for proteasomal mediated degradation, without altering XIAP levels 43,44.  
Indeed, immunoblot analysis of U2OS cell lysates prepared from cells treated with 
LCL161 revealed a rapid and specific reduction of cIAP1, which was observed as 
quickly as 30 min after treatment and persisted for the course of the migration 
experiment (Figure 4B).  As we could suppress cIAP1 levels, without altering XIAP, 
we measured cell migration rates in LCL161 treated cells.  Cell migration was not 
significantly altered in cells treated with LCL161 (Figure 4C).  The data suggest 
that chemical depletion of cIAP proteins does not alter cell migration rates in U2OS 
cells. 
 
XIAP E3 ubiquitin Ligase Activity is Required to Suppress Cell Migration 
The XIAP protein has dual enzymatic activities, by virtue of its ability to bind 
caspases via its BIR domains and its E3 ubiquitin ligase activity conferred by the 
C-terminal RING domain (Figure 5A).  To investigate what properties of XIAP are 
necessary for the control of cell migration in U2OS cells, wildtype XIAP and XIAP 
variants were transfected into XIAP null cell lines.  Based on the crystal structures 
of XIAP, specific point mutations have been characterized that can alter specific 
properties of the protein 5,6.  To examine the properties of XIAP required for its 
ability to regulate cell migration we reconstituted XIAP null cells with wildtype XIAP, 
a caspase 3/7/9 binding mutant (D148A/ W310A) 45,46 or an E3 ubiquitin ligase 
mutant (F495A) 47 (Figure 5A).  Immunoblot analysis revealed that each XIAP 
variant was expressed to equivalent levels in XIAP-null cells (Figure 5B).  Cells 
reconstituted with wildtype XIAP or the caspase-binding mutant (D148A/ W310A), 
significantly inhibited the migration of XIAP deficient cells as compared to the 
XIAP-deleted control cell line transfected with empty vector (Figure 5C and 5D). 
However, reconstitution with the XIAP ubiquitin ligase mutant, F495A, failed to 
reverse the increased migration phenotype, indicating that the ubiquitin ligase 
activity of XIAP is essential for its ability to regulate cell motility in cells (Figure 5C 
and 5D). 
 
XIAP regulates levels of the C-RAF protein kinase to regulate cell motility 
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Previous studies have shown that XIAP can suppress cell migration by 
binding to and ubiquitinating C-RAF and Cdc42, key proteins involved in cell 
motility, marking then for proteasomal degradation.  48 26.  C-RAF, a 
serine/threonine kinase in the MAP kinase signaling cascade, is  a well-described 
promotor of cell migration and motility, and Cdc42 is a RhoGTPase that controls 
filopodia formation and cell migration48 23,26.  As our data suggested that XIAP 
suppresses migration rates we examined levels of C-RAF and Cdc42 in the XIAP 
null cells.  Immunoblot analysis of cell lysates prepared from XIAP wildtype and 
XIAP null cell lines indicate that XIAP null cells have elevated levels of C-RAF 
protein, but not elevated levels of Cdc42 (Figure 6A and 6B, Supplementary Figure 
5B and C).  To investigate if expression of XIAP could reduce C-RAF levels, XIAP 
null cells were transfected with plasmids encoding wildtype XIAP or empty vector.  
Expression of XIAP reduced levels of C-RAF compared those observed in XIAP 
null cells (Figure 6C, Supplementary 5C).  Our data indicate that C-RAF levels, but 
not Cdc42,  are elevated in XIAP-null cells, and C-RAF levels can be reduced by 
re-introducing wildtype XIAP. 
Therefore, we decided to investigate the role of C-RAF activity in regulating 
the rates of migration and motility.  To suppress C-RAF activity XIAP-null cells 
were treated with the C-RAF kinase inhibitor, BAY 43-9006 49 .  XIAP wildtype and 
knockout cells were pretreated BAY 43-9006, and cell migration rates were 
determined by wound healing assay compared to cells treated with vehicle alone.  
The migration rates of XIAP-null cells was significantly suppressed by the C-RAF 
inhibitor, indicating that C-RAF levels and activity were at least in part responsible 
for the increased migration rates in the XIAP-null cells (Figure 6D).   
Taken together these results indicate that XIAP deletion results in enhanced 
cellular migration rates.  We find that it is the ubiquitin ligase activity of XIAP is 
important for the migration phenotype, through regulation of the levels of the C-
RAF protein kinase.  In addition, we show that chemical inhibition of C-RAF 









The results of the present study indicate that XIAP plays an important role 
in controlling cell migration rates.  Our data, using CRISPR/Cas9 and TALEN 
modified cell lines demonstrate that XIAP deletion increases the motility of U2OS 
cells, by controlling the levels of the C-RAF protein kinase.  Reconstitution of our 
XIAP-null cell lines with wildtype XIAP, and XIAP variants, suppress C-RAF levels 
and reduce cell motility, in a manner dependent on XIAP ubiquitin ligase activity.  
C-RAF protein levels are elevated in XIAP-null cells and reduced when XIAP is re-
expressed.  Importantly, treatment of XIAP-null cells with a C-RAF kinase inhibitor 
is sufficient to supress the increased cell migration rates. 
XIAP is a well-described inhibitor of caspase-3, -7 and -9 activity, with 
overexpression of the XIAP protein a well-defined suppressor of cell death 5,7,29,39.  
As such a number of drugs that directly target XIAP are in development and these 
inhibitors might enhance chemosensitivity in XIAP over-expressing tumours50–52.  
However, the cellular role of endogenous XIAP in the regulation apoptotic cell 
death is less clear.  The XIAP-null mouse is born at expected Mendalian ratios with 
no obvious cell death related phenotype 53.  Instead, many studies have indicated 
that a key role for the IAP family of proteins is to act as E3 ubiquitin ligases to 
regulate multiple cellular processes.  Indeed, XIAP deficiency can result in more 
aggressive disease in a murine prostate cancer model which suggests a degree 
of caution to be employed before XIAP antagonists are used for cancer therapy54. 
Several studies have previously demonstrated a link between XIAP and 
cIAP levels and cell motility/ migration 28.  XIAP deletion or depletion has been 
reported to increase cell migration and motility through increasing levels of C-RAF 
and Cdc42 23 26.  However, conflicting reports have demonstrated that XIAP can 
negatively regulate RhoGDI activity by modulating its SUMOylation, thereby 
increasing actin polymerization and cell motility, resulting in XIAP depletion 
causing decreases in cell migration 24 55 56.  These conflicting results may arise by 
localised differences of the downstream IAP signalling molecules in each individual 
cell type.  Results from cell lines used our study show that XIAP deletion increases 
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levels of C-RAF, and C-RAF inhibition reduced the migratory capacity of XIAP 
deficient cells lines. 
Our data show that XIAP dependent control of cell migration is at least in 
part due to its ability to modulate the levels of the C-RAF protein kinase.  A major 
challenge in understanding XIAP-deficient disease is reconciling the cellular 
properties of XIAP with the symptoms associated disease.  One of the major 
symptoms associated with XIAP deficiency is the development of severe 
haemorrhagic colitis, which is associated with its key role in inflammatory signalling 
through the NOD signalling pathway 57–60.  However, XIAP-deficient patients also 
present with hemophagocytic lymphohistiocytosis (HLH), recurrent fevers, 
recurrent low blood counts and splenomegaly, which may be due to XIAP’s role in 
regulating caspases or alternative signalling pathways 61.  Interestingly, in the 
context of the current study, it has been reported that constitutively active 
mitochondrial C-RAF can also result in mild to moderate splenomegaly 62.  Indeed, 
expression of a kinase-activating C-RAF mutant, C-RAF(L613V), in a murine 
model of Noonan syndrome, results in splenomegaly, a phenotype also associated 
with XIAP-deficient patients 63.  It would be interesting to investigate if the 
regulation of C-RAF and cell migration by XIAP has any role in the progression of 
XLP2, either through spleen enlargement or progression of any of the other 
phenotypes.   
Collectively our data reveal that XIAP has a critical role in regulating cell 
migration through its ability to polyubiquitinate and target C-RAF for proteolytic 
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Figure 1 Creation of XIAP null cell lines.  A. Schematic of the exon structure of 
the XIAP gene and the domains of the XIAP protein.  Location of the CRISPR 
gRNA binding site and the diagnostic PCR primers are indicated.  B. PCR analysis 
of genomic DNA prepared from U2OS clonal cell lines prepared from 
CRISPR/Cas9 transfected cells.  C.  Alignment of the sequencing data of XIAP 
exon 1 from clonal cells lines.  Whole cell lysates were prepared from CRISPR/ 
Cas9 monoclonal U2OS cells. Lysates were subjected to immunoblot analysis to 
assess XIAP expression levels using  D. an XIAP antibody from BD (immunogen 
amino acids 268-426) and  E. an Abcam XIAP antibody (immunogen amino acids 
352-449). 
 
Figure 2  XIAP status does not alter cell viability in response to cytotoxic 
agents   A. U2OS clonal cell lines were exposed to etoposide for 48 hours and 
viability was determined by PrestoBlue assay.  The normalised mean fluorescence 
intensity (MFI) at increasing concentrations of etoposide (log2(mM)) of three 
independent experiments for each clone is averaged and plotted (Individual 
repeats shown in Supp Figure 1A).  Statistical analysis performed using a one-way 
ANOVA with Dunnett’s multiple comparisons test.  B.  As in A but using 
doxorubicin.  C.  The mean normalised IC50 (mM) for etoposide is plotted for each 
clone.    D.  As in C. but for doxorubicin.  E. U2OS clonal cell lines treated with 
50uM Etoposide for 24h as indicated. Caspase-3 -7 activity was determined by 
Caspase-Glo assay and values normalised to untreated controls. Error bars 
represent standard deviation.  Statistical analysis performed using a one-way 
ANOVA with Dunnett’s multiple comparisons test. 
 
Figure 3 XIAP-null cells have increased migratory capacity.  A.  
Representative images of a wound healing experiment for wild type and XIAP null 
clones at 0 and 24 hours. The migration front is highlighted for clarity.  B.  The area 
of the wound was imaged and measured at 0, 8, and 24 hours using ImageJ 
	 28	
software.  The data was normalised with the percentage wound area equalling 
100% at 0 hours. The % wound area was plotted against time and the area under 
the curve (% wound area x time(hours)) was calculated and analysed by one-way 
ANOVA using Dunnett multiple comparisons test in comparison to the wildtype 
clone 1.  Each measurement represents data from an individual scratch. Statistical 
analysis performed using a one-way ANOVA with Dunnett’s multiple comparisons 
test C. As in B. using independent XIAP-null clonal cell lines.  D.  Proliferation 
assay performed using Prestoblue assay.  Cell lines and measurement times as 
indicated. 
 
Figure 4.  cIAP proteins does not significantly alter U2OS cell motility.  A.  
Whole cell lysates were prepared from CRISPR/ Cas9 monoclonal U2OS cells.  
Lysates were subjected to immunoblot analysis to assess cIAP1 levels.  B. 
Wildtype U2OS cells were treated with the SMAC mimetic compound, LCL161, for 
the indicated times.   Whole cell lysates were prepared and analysed by 
immunoblot analysis using the indicated antibodies.  C.  Wound healing assays 
were performed on untreated and LCL161 treated U2OS cells and measured at 0, 
8 and 24 hours.  The area of the wound was imaged and measured at 0, 8, and 24 
hours using ImageJ software.  The data was normalised with the percentage 
wound area equalling 100% at 0 hours. The % wound area was plotted against 
time and the area under the curve (% wound area x time(hours)) was calculated 
and analysed by unpaired students t-test.   
 
Figure 5.  The ubiquitin ligase activity of XIAP is necessary to control cell 
migration rates.  A.  Schematic of XIAP protein indicating key residues essential 
for mediating the caspase interactions and the E3 ubiquitin ligase activity.  B.  
Representative images of a wound healing experiment using XIAP KO clone 2 
transfected with empty vector, wildtype XIAP, caspase binding mutant XIAP 
(D148A/ W310A), and ubiquitin ligase mutant XIAP (F495A), and XIAP WT clone 
1 transfected with empty vector at 0 and 24 hours. The migration front is highlighted 
for clarity. C.  Whole cell lysates prepared from transfected cells and 
	 29	
immunoblotted with XIAP and actin antibodies to determine transfection efficiency.  
D.  The area of the wound was imaged and measured at 0, 8, and 24 hours using 
ImageJ software.  The data was normalised with the percentage wound area 
equalling 100% at 0 hours. The % wound area was plotted against time and the 
area under the curve (% wound area x time(hours)) was calculated and analysed 
by one-way ANOVA using Dunnett multiple comparisons test in comparison to the 
XIAP KO clone 2 transfected with empty vector. 
 
Figure 6.  XIAP controls levels of C-RAF to influence cell migration.  A,B. 
Whole cell lysates were prepared from CRISPR/ Cas9 monoclonal U2OS cells and 
immunoblotted using the indicated antibodies. C.   The area of the wound of XIAP 
null cells (KO 2) treated with the C-RAF inhibitor, BAY 43-9006,  was imaged and 
measured at 0, 8, and 24 hours using ImageJ software.  The data was normalised 
with the percentage wound area equalling 100% at 0 hours.  The % wound area 
was plotted against time and the area under the curve (% wound area x 






1 2 3 4 5 6
NH2 BIR1 BIR3BIR2 RING
26 93 163 230 265 330 446 485 497aa
COOH
ATG 878 978 1057 1100 1301 TAA
UBA
367 419











































































































- + - + - + LCL 161


































































































































































































































































Supplementary Figure 1.  A.  U2OS clonal cell lines were exposed to etoposide 
for 48 hours and viability was determined by PrestoBlue assay.  The fluorescence 
intensity was measure and each data set were normalised to the reading from 
untreated cells. The normalised mean fluorescence intensity (MFI) at increasing 
concentrations of etoposide (log2(mM)) for each clonal cell line is shown. Only 
data sets with a value of R2>0.85 were used and each curve represents the 
individual experimental repeats used to calculate the averages used in Figure 2A.  
B. As in (A), but using Doxorubicin as the cytotoxic agent.   
 
Supplementary Figure 2.  XIAP-null cells have increased migratory capacity.    
A Representative images of a wound healing experiment for wild type and XIAP 
null clones at 0 and 24 hours. The migration front is highlighted for clarity. B  
Representative images of the migration front for wild type and XIAP null clones at 
0 and 24 hours. C The length of the migration front was measured at 0 and 24hr 
using Image J software.  The migration front length was plotted and analysed by 
unpaired students t-test. 
 
 
Supplementary Figure 3.  XIAP-null cells have increased migratory capacity 
A DNA sequence of the first exon of the XIAP gene with the TALEN binding sites 
indicated and allignments of DNA sequencing analysis of TALEN modified clonal 
U2OS cell lines.  B PCR analysis of the genomic DNA of TALEN modified U2OS 
cell line using primers spanning the sites of TALEN-mediated cleavage.  C. Whole 
cell lysates were prepared from TALEN-modified U2OS clonal cell lines.  Lysates 
were subjected to immunoblot analysis to assess XIAP expression levels using a 
specific XIAP antibody (BD).  D Representative images of a wound healing 
experiment for wild type and XIAP null clones at 0 and 24 hours. The migration 
front is highlighted for clarity.  E The area of the wound was imaged and measured 
at 0, 8, and 24 hours using ImageJ software.  The data was normalised with the 
percentage wound area equalling 100% at 0 hours. The % wound area was plotted 
against time and the area under the curve (% wound area x time(hours)) was 
calculated and analysed by unpaired students t-test. 
 
Supplementary Figure 4.  XIAP-depleted HeLa cells have increased migratory 
capacity.  A  HeLa cells transfected with the indicated siRNAs, whole-cell lysates 
(WCLs) prepared from these cells were subjected to immunoblot analysis to 
assess expression levels of the indicated proteins.  B Representative images of a 
wound healing experiment for control and XIAP-depleted cells at 0 and 24 hours. 
The migration front is highlighted for clarity.  The area of the wound was imaged 
and measured at 0 and 24 hours using ImageJ software.  C The data was 
normalised with the percentage wound area equalling 100% at 0 hours. The % 
wound area was plotted against time and the area under the curve (% wound area 
x time(hours)) was calculated and analysed by unpaired students t-test.  24 
scratches were measured (8 technical replicates from 3 independent 
experiments).   
 
Supplementary Figure 5 XIAP controls levels of C-RAF to influence cell 
migration.  The relative abundance of proteins A cIAP1 B C-RAF C Cdc42 as 
compared to b-actin were quantified from 3 independent experiments in XIAP WT 
and KO cells using ImageJ software.  Abundance was normalised to the mean of 
the 2 WT cell lines.  Statistical analysis performed using a one-way ANOVA with 
Dunnett’s multiple comparisons test and compared to the XIAP WT Clone 1.  D. 
Relative abundance of C-RAF as compared to b-actin was quantified from 3 
independent experimetns in XIAP KO cells transfected with empty vector or HA-
XIAP.  Abundance was normalised to the mean of the XIAP KO cell lines 
transfected with empty vector.  Statistical analysis performed using a one-way 
ANOVA with Dunnett’s multiple comparisons test and compared to the XIAP KO 








and  was generated by quantifying blots from three independent experiments 
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XIAP        100-ctaattttccaagtggtagtcctgtttcagcatcaacactggcacgagcagggtttctttatactggtgaaggagatacc-170
TALEN WT 1  100-ctaattttccaagtggtagtcctgtttcagcatcaacactggcacgagcagggtttctttatactggtgaaggagatacc-179
TALEN WT 2 100-ctaattttccaagtggtagtcctgtttcagcatcaacactggcacgagcagggtttctttatactggtgaaggagatacc-179
TALEN KO 1 100-ctaattttccaagtggtagtcctgtttcagcatcaacactggcacga----------tttatactggtgaaggagatacc-169
TALEN WT 3 100-ctaattttccaagtggtagtcctgtttcagcatcaacactggcacgagcagggtttctttatactggtgaaggagatacc-179
TALEN Left TALEN Right
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